Physician profile

Saluna Baiju

Nurse Practitioner · Philadelphia, PA

NPI 1285205831

$641.96

in general payments reported to CMS, 2019-2025

8 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$536.31

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Janssen Pharmaceuticals, INC $401.44 2023-2024 Xarelto, Invega Sustenna, Invega Trinza
Indivior INC. $82.05 2022-2023 Perseris
Alkermes, INC. $45.43 2022
Gilead Sciences, INC. $31.10 2023-2024 Biktarvy
Otsuka America Pharmaceutical, INC. $24.12 2023 Rexulti, Abilify Maintena
Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) $23.00 2023
Braeburn INC. $18.96 2024 Brixadi
Neurocrine Biosciences, INC. $15.86 2023 Ingrezza

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Saluna Baiju

$641.96

in general payments reported 2019-2025

Years
2022-2024
Top company
Janssen Pharmaceuticals, INC

https://glasscript.com/doctor/10692499/saluna-baiju

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.